Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

82.12B

Market cap82.12B

Price-Earnings ratio

18.76

Price-Earnings ratio18.76

Dividend yield

0.48%

Dividend yield0.48%

Average volume

900.74K

Average volume900.74K

High today

$785.98

High today$785.98

Low today

$767.82

Low today$767.82

Open price

$774.47

Open price$774.47

Volume

552.07K

Volume552.07K

52 Week high

$821.11

52 Week high$821.11

52 Week low

$541.00

52 Week low$541.00

Stock Snapshot

With a market cap of 82.12B, Regeneron(REGN) trades at $784.36. The stock has a price-to-earnings ratio of 18.76 and currently yields dividends of 0.48%.

As of 2026-08-09, Regeneron(REGN) stock has fluctuated between $767.82 and $785.98. The current price stands at $784.36, placing the stock +2.2% above today's low and -0.2% off the high.

Regeneron(REGN) shares are trading with a volume of 552.07K, against a daily average of 900.74K.

During the past year, Regeneron(REGN) stock moved between $541.00 at its lowest and $821.11 at its peak.

REGN News

MarketWatch 2d

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

...

TipRanks 3d

Regeneron announces Health Canada approval of new indication for Libtayo

Regeneron (REGN) Canada announced that Health Canada has issued a Notice of Compliance for Libtayo for the adjuvant treatment of adult patients with cutaneous s...

TipRanks 4d

Regeneron Targets Next‑Gen Cancer Immunotherapy With New Phase 1/2 Trial

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, mo...

Analyst ratings

63%

of 30 ratings

Buy

63.3%

Hold

36.7%

Sell

More REGN News

Simply Wall St 5d

Does Regeneron Prioritize Shareholder Returns Over Earnings Quality As Profit Slips Amid Rising Sales?

Regeneron Pharmaceuticals, Inc. previously reported second-quarter 2026 revenue of US$4,290.7 million versus US$3,675.6 million a year earlier, while net income...

TipRanks 6d

Regeneron price target raised to $1,030 from $1,000 at Guggenheim

Guggenheim raised the firm’s price target on Regeneron (REGN) to $1,030 from $1,000 and keeps a Buy rating on the shares following what the firm calls ” a clean...

Simply Wall St 6d

Regeneron Pharmaceuticals Posts Strong Q2 Revenue, Is The Upside Already Priced In?

Regeneron Pharmaceuticals (REGN) is back in focus after reporting second quarter 2026 results that showed revenue of US$4.29b, alongside a quarterly dividend de...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.